Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Balancing efficacy and tolerability in multiple myeloma

Patrizia Tosi • 21 Sep 2020
SOHO Italy 2020
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T

Patrizia Tosi, MD, Infermi Hospital, Rimini, Italy, discusses the importance of balancing efficacy and toxicity in the era of novel agents in the treatment of multiple myeloma. Dr Tosi also discusses side effects associated with monoclonal antibodies and cellular therapies such as hematological toxicities as well as highlighting belantamab mafodotin, a efficacious antibody-drug conjugate in multiple myeloma with corneal side effects. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals